BioSupply Trends Quarterly logo
Close this search box.

The Protective Value of RSV Vaccines in Older Adults: A Deeper Dive

Now that safe and effective RSV vaccines are finally available, more evidence of their direct health benefits in older Americans will be forthcoming. It is likely as well that FDA will eventually expand the marketing approvals of these vaccines to include adults under age 60 with chronic conditions demonstrated to importantly increase the risk of RSV-associated LRTD and hospitalization.

The Anti-Vaccine Movement: Where Are We Now?

Despite scientific evidence to the contrary, doubts about vaccine safety and efficacy have not only persisted, but escalated. Counteracting this wave of mistrust will require targeted tactics and networked, community involvement.